1,2,3,4-Tetrahydrochinolin-8-carboxamid | 53400-59-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: 1,2,3,4-Tetrahydrochinolin-8-carboxamid
• 英文别名: 5,6,7,8-Tetrahydrochinolin-8-carboxamid；5,6,7,8-tetrahydro-quinoline-8-carboxylic acid amide；5,6,7,8-tetrahydroquinoline-8-carboxamide
• CAS: 53400-59-2
• 化学式: C₁₀H₁₂N₂O
• 分子量: 176.218
• InChiKey: KORYAMUIXKTLTJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.7
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  56
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  1,2,3,4-Tetrahydrochinolin-8-carboxamid 以72%的产率得到
  参考文献：
  名称：

  CROSSLEY R.; CURRAN A. C. W.; HILL D. G., J. CHEM. SOC. PERKIN TRANS, PART 1 , 1976, NO 9, 977-982

  摘要：

  DOI：
• 作为产物：
  描述：

  5,6,7,8-tetrahydroquinoline-8-carboxylic acid methyl ester 在 氨 作用下， 以 甲醇 为溶剂， 生成 1,2,3,4-Tetrahydrochinolin-8-carboxamid
  参考文献：
  名称：

  8-Carboxylester, and 8-carbamyl derivitives of

  摘要：

  这项发明涉及一种新颖的5,6,7,8-四氢喹啉衍生物，其在8位具有一个称为基团X的基团，其中基团X为CONHR.sup.3，或CO.sub.2R.sup.5，其中R.sup.3为氢、低碳链烷基，R.sup.5为氢、低碳链烷基或低碳链芳基基团。这些化合物是相应化合物的中间体，其中X为CSNHR.sup.3，这些化合物是抗溃疡药物。

  公开号：

  US04009169A1

文献信息

• 8-Carboxylester, and 8-carbamyl derivitives of
  申请人：John Wyeth & Brother Limited

  公开号：US04009169A1

  公开（公告）日：1977-02-22

  The invention relates to novel 5,6,7,8-tetrahydroquinoline derivatives which have a group X situated at the 8-position said group X is CONHR.sup.3, or CO.sub.2 R.sup.5 wherein R.sup.3 is hydrogen lower alkyl and R.sup.5 is hydrogen, lower alkyl or a lower aralkyl radical. The compounds are intermediates for corresponding compounds where X is CSNHR.sup.3 and these are anti-ulcer agents.

  这项发明涉及一种新颖的5,6,7,8-四氢喹啉衍生物，其在8位具有一个称为基团X的基团，其中基团X为CONHR.sup.3，或CO.sub.2R.sup.5，其中R.sup.3为氢、低碳链烷基，R.sup.5为氢、低碳链烷基或低碳链芳基基团。这些化合物是相应化合物的中间体，其中X为CSNHR.sup.3，这些化合物是抗溃疡药物。
• 8-Cyano-5,6,7,8-tetrahydroquinoline derivatives
  申请人：John Wyeth & Brother Limited

  公开号：US04011225A1

  公开（公告）日：1977-03-08

  The invention relates to novel 8-cyano-5,6,7,8-tetrahydroquinoline derivatives which are intermediates for the preparation of corresponding 8-thioamides. Some of the 8-cyano compounds are anti-ulcer agents.

  这项发明涉及一种新型的8-氰基-5,6,7,8-四氢喹啉衍生物，这些衍生物是制备相应的8-硫代酰胺的中间体。其中一些8-氰基化合物是抗溃疡药物。
• Cyclopenteno[b]pyridine derivatives
  申请人：John Wyeth & Brother Limited

  公开号：US04029668A1

  公开（公告）日：1977-06-14

  The invention relates to novel cyclopenteno[b]pyridine derivatives which have a group X on the 7-position and related tricyclic compounds. X is CONHR.sup.3, or CO.sub.2 R.sup.5 wherein R.sup.3 is hydrogen or lower alkyl and R.sup.5 is hydrogen or a lower alkyl or lower aralkyl group which may be substituted by alkyl, alkoxy, halogen, nitro or trifluoromethyl; other substituents may be present. The compounds are intermediates for compounds wherein X is CSNHR.sup.3 which are anti-ulcer agents.

  该发明涉及具有7-位上的X基团的新型环戊烯基吡啶衍生物及相关的三环化合物。X为CONHR.sup.3，或CO.sub.2R.sup.5，其中R.sup.3为氢或较低的烷基，R.sup.5为氢或较低的烷基或较低的芳基烷基，可能被烷基、烷氧基、卤素、硝基或三氟甲基取代；其他取代基可能存在。这些化合物是X为CSNHR.sup.3的化合物的中间体，这些化合物是抗溃疡药物。
• Certain 5,6,7,8-tetrahydroquinoline-8-thiocarboxamides
  申请人：John Wyeth & Brother Ltd.

  公开号：US04085215A1

  公开（公告）日：1978-04-18

  The invention relates to novel pyridine derivatives which have a fused 5,6, or 7-membered saturated hydrocarbon ring adjacent to the nitrogen of the pyridine ring, and a group X situated on said hydrocarbon ring and separated by one carbon atom from the pyridine nitrogen atom, said group X is cyano, CONHR.sup.3, CSNHR.sup.3 or CO.sub.2 R.sup.5 wherein R.sup.3 is selected from hydrogen, lower alkyl and lower aralkyl radicals and R.sup.5 is selected from hydrogen, lower alkyl and lower aralkyl radicals which may be substituted by alkyl, alkoxy, halogen, nitro or trifluoromethyl; other substituents may be present. Compounds wherein X is CSNHR.sup.3 are anti-ulcer agents and the other compounds are intermediates therefor.

  该发明涉及具有与吡啶环的氮相邻的融合的5、6或7成员饱和碳氢环的新型吡啶衍生物，以及位于所述碳氢环上并且与吡啶氮原子相隔一个碳原子的基团X，所述基团X为氰基、CONHR.sup.3、CSNHR.sup.3或CO.sub.2R.sup.5，其中R.sup.3从氢、较低的烷基和较低的芳基烷基基团中选择，R.sup.5从氢、较低的烷基和较低的芳基烷基基团中选择，可以被烷基、烷氧基、卤素、硝基或三氟甲基取代；其他取代基也可以存在。其中X为CSNHR.sup.3的化合物是抗溃疡剂，其他化合物是其中间体。
• [EN] PYRIDINE, BICYCLIC PYRIDINE AND RELATED ANALOGS AS SIRTUIN MODULATORS<br/>[FR] PYRIDINE, PYRIDINE BICYCLIQUE ET ANALOGUES ASSOCIÉS EN TANT QUE MODULATEURS DE SIRTUINE
  申请人：SIRTRIS PHARMACEUTICALS INC

  公开号：WO2010056549A1

  公开（公告）日：2010-05-20

  The present invention provides novel sirtuin-modulating compounds and methods of use thereof. The sirtuin-modulating compounds may be used for increasing the lifespan of a cell, and treating and/or preventing a wide variety of diseases and disorders relating to aging or stress, diabetes, obesity, neurodegenerative disease, cardiovascular disease, blood clotting disorders, inflammation, cancer, and/or flushing as well as diseases or disorder that would benefit from increased mitochondrial activity. Also provided are compositions comprising a sirtuin-modulating compound in combination with another therapeutic agent. The compounds are of general formula (III) wherein R1, R2, R", X, Y, W, Z1 and Z2 are as defined in the specification.

  本发明提供了新颖的调节sirtuin的化合物以及其使用方法。这些调节sirtuin的化合物可用于延长细胞寿命，并用于治疗和/或预防与衰老或压力、糖尿病、肥胖、神经退行性疾病、心血管疾病、血液凝块障碍、炎症、癌症、潮红以及需要增加线粒体活性的疾病或疾病。还提供了包含sirtuin调节化合物与另一治疗剂组合的组合物。这些化合物的一般化学式为（III），其中R1、R2、R"、X、Y、W、Z1和Z2如规范中定义。